Prognostic and clinicopathological significance of MicroRNA-153 in human cancers: A meta-analysis

BACKGROUND: Several studies have explored the prognostic value of MicroRNA-153 (miR-153) in various cancers, but obtained inconsistent results. Thus, we conducted a meta-analysis to assess the prognostic significance of miR-153 for patients with cancer. METHODS: Eligible studies were identified by searching the online databases Pubmed, Embase, Web of Science, Medline,and the China National Knowledge Infrastructure (CNKI) up to March 2020. Hazard ratios (HRs) with 95% CIs and were calculated to clarify the correlation between miR-153 expression and prognosis of different cancers. Odds ratios (ORs) with 95% CI were selected to appraise the correlation between miR-153 with clinicopathological characteristics of cancer patients. RESULTS: In total, 933 patients from 11 articles were enrolled in our meta-analysis. The results revealed that low miR-153 expression was significantly correlated with poor overall survival (OS) (HR = 2.45, 95% CI = 1.66–3.63, P < .001), but not with disease-free survival (DFS) (HR = 1.67, 95% CI = 0.45–6.19, P = .442). Subgroup analysis found that low miR-153 expression was associated with worse OS in the reported directly from articles group (HR = 2.67, 95% CI: 1.32–5.37, P = .006), survival curves group (HR = 2.10, 95% CI: 1.56–2.84, P < .001), digestive system tumor (HR = 2.76, 95% CI: 1.73–4.41, P < .001), and breast cancer (HR = 4.01, 95% CI: 1.46–11.04, P = .007). Moreover, cancer patients with low miR-153 expression were prone to poor tumor differentiation(poor vs well+moderate, OR = 2.41, 95% CI = 1.52–3.82, P < .001), earlier lymph node metastasis (present vs absent, OR = 2.19, 95% CI = 1.12–4.25, P = .021) and earlier distant metastasis (present vs absent,OR = 8.24, 95% CI = 2.93–23.21, P < .001), but not associated with age,gender and TNM stage. CONCLUSIONS: This meta-analysis indicated that low miR-153 expression is associated with poor prognosis. miR-153 may serve as an effective predictive biomarker for tumor prognosis, especially for digestive system tumor and breast cancer.